A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Trial Profile

A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs MCS 110 (Primary) ; PDR 001 (Primary)
  • Indications Breast cancer; Endometrial cancer; Malignant melanoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 03 Nov 2017 Planned number of patients changed from 196 to 175.
    • 17 May 2017 Planned number of patients changed from 175 to 196.
    • 27 Feb 2017 Planned primary completion date changed from 1 Jun 2019 to 29 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top